Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

Girard, N.; Galland-Girodet, S.; Avrillon, V.; Besse, B.; Duruisseaux, M.; Cadranel, J.; Otto, J.; Prevost, A.; Roch, B.; Bennouna, J.; Bouledrak, K.; Coudurier, M.; Egenod, T.; Lamy, R.; Ricordel, C.; Moro-Sibilot, D.; Odier, L.; Tillon-Strozyk, J.; Zalcman, G.; Missy, P.; Westeel, V.; Baldacci, S.

Published in

Esmo Open, Esmo Open, 2(7), p. 100418, 2022

DOI: 10.1016/j.esmoop.2022.100418

Tools

Export citation

Search in Google Scholar

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

Journal article published in 2022 by N. Girard, S. Galland-Girodet, V. Avrillon, B. Besse, M. Duruisseaux, J. Cadranel, J. Otto, A. Prevost, B. Roch, J. Bennouna, K. Bouledrak, M. Coudurier, T. Egenod, R. Lamy, C. Ricordel and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload

Policy details

Data provided by

Published in

Links

Tools

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study